Department of Epidemic Cell, Central Council for Research in Homoeopathy, Janakpuri, New Delhi, India.
Department of Clinical Research, Dr. D.P Rastogi Central Research Institute of Homoeopathy, Noida, Uttar Pradesh, India.
Homeopathy. 2022 Nov;111(4):261-270. doi: 10.1055/s-0042-1745755. Epub 2022 Jun 29.
This work was undertaken to evaluate the protective effect of 30C against COVID-19.
The work was designed as a prospective parallel cluster cohort study.
Participants were enrolled in a homeopathy intervention (HI) cohort (who received ) or in a non-intervention (NI) cohort (who received no systematic intervention) from COVID-19 containment areas of Delhi. Individuals of age 5 years or above were given four medicated pills of 30C, while those from 1 to 5 years old were given two medicated pills in each dose.
The analysis included 10,180 individuals residing in 11 COVID-19 containment areas in Delhi, out of which 6,590 individuals were in the HI cohort and 3,590 individuals were in the NI cohort. The overall protective effect of 30C was 83.43% (95% confidence interval [CI], 76.77 to 88.17): 45 cases per 6,590 (8.34 per 10,000 person-weeks) in the 30C group versus 143 cases per 3,590 (45.01 per 10,000 person-weeks) in the NI cohort. The protective effect of 30C against laboratory confirmed COVID-19 was 74.40% (95% CI, 55.08 to 85.41): 18 cases per 6,590 (3.32 per 10,000 person-weeks) in the 30C group versus 38 cases per 3,590 (11.85 per 10,000 person-weeks) in the NI cohort.
The use of 30C was associated with some protection against probable and laboratory-confirmed COVID-19 in a containment-zone setting. Randomized controlled trials are needed to confirm or refute these results.
本研究旨在评估顺势疗法 30C 对 COVID-19 的保护作用。
前瞻性平行集群队列研究。
从德里的 COVID-19 隔离区招募参与者进入顺势疗法干预（HI）队列（接受顺势疗法治疗）或非干预（NI）队列（未接受系统干预）。5 岁及以上个体给予 4 粒 30C 调制药丸，1 至 5 岁个体每次给予 2 粒调制药丸。
分析纳入了德里 11 个 COVID-19 隔离区的 10180 名居民，其中 6590 名个体在 HI 队列，3590 名个体在 NI 队列。30C 的总体保护作用为 83.43%（95%置信区间[CI]，76.77 至 88.17）：30C 组每 6590 人中有 45 例（8.34 例/10000 人周），NI 队列中每 3590 人中有 143 例（45.01 例/10000 人周）。30C 对实验室确诊 COVID-19 的保护作用为 74.40%（95%CI，55.08 至 85.41）：30C 组每 6590 人中有 18 例（3.32 例/10000 人周），NI 队列中每 3590 人中有 38 例（11.85 例/10000 人周）。
在隔离区环境中，使用 30C 可能对疑似和实验室确诊 COVID-19 具有一定的保护作用。需要开展随机对照试验来证实或反驳这些结果。
